Systolic vs. Diastolic Dysfunction: Key Differences

Systolic dysfunction means the heart cannot squeeze forcefully enough to push blood out, while diastolic dysfunction means the heart cannot relax and fill properly between beats. That single-sentence distinction sounds tidy, but it barely scratches the surface. The two conditions differ in who they tend to strike, how they’re diagnosed, what drives them at the tissue level, and which treatments actually work. They can also coexist, and a recently recognized middle category blurs the boundary further.

The Core Mechanical Difference

During each heartbeat, the left ventricle goes through two phases. In systole it contracts, pushing oxygen-rich blood into the aorta and out to the body. In diastole it relaxes, filling back up with blood from the lungs. Dysfunction in either phase can produce heart failure, but the underlying muscle problem is different.

In systolic dysfunction, the heart muscle loses its ability to generate enough force. This happens when heart cells die off, when the remaining cells become disorganized, or when the muscle fibers thin out, all of which reduce the heart’s squeezing power and lead to a drop in ejection fraction, the percentage of blood pushed out with each beat.¹ A normal ejection fraction runs roughly 55 to 70 percent. In systolic heart failure, it falls below 40 percent.

In diastolic dysfunction, the ejection fraction stays normal or near-normal, but the ventricle becomes stiff and resists filling. A giant spring-like protein called titin, which sits inside every heart muscle cell, plays a central role. Changes in how titin is chemically modified, along with a buildup of scar-like collagen between cells, increase the passive stiffness of the heart wall.² Because the ventricle cannot stretch open easily, filling pressures climb and blood backs up into the lungs, causing shortness of breath and fluid retention even though the pump appears to be squeezing just fine.

How the Heart Remodels Differently

The structural changes that accompany each type of dysfunction also diverge. When the heart faces chronic pressure overload, as in long-standing high blood pressure, the muscle wall thickens inward. The individual contractile units inside the cells replicate side by side, making the wall bulkier without enlarging the chamber. This concentric pattern is a hallmark of diastolic dysfunction.³

Volume overload, on the other hand, stretches the chamber. The contractile units replicate end to end, elongating the cells and dilating the ventricle. This eccentric remodeling is the classic shape change in systolic dysfunction after a large heart attack, where dead tissue is replaced by scar and the surviving muscle stretches to compensate.³ Recognizing concentric versus eccentric remodeling on imaging helps clinicians predict which type of dysfunction is dominant.

How Each Type Is Diagnosed

The single most important test is an echocardiogram, an ultrasound of the heart. Systolic dysfunction is straightforward to spot: you measure how well the ventricle contracts and calculate the ejection fraction. If it is reduced, the diagnosis is clear.⁴

Diastolic dysfunction is trickier. The ejection fraction looks normal, so clinicians rely on indirect markers: how fast blood flows through the mitral valve during early and late filling, how the heart muscle itself moves during relaxation, and how large the left atrium has become from chronic pressure backup. These measurements, combined with a clinical picture of heart failure symptoms, allow the diagnosis of what is now called heart failure with preserved ejection fraction.⁴

A blood test for a molecule called BNP (or its relative NT-proBNP) helps confirm heart failure in general, but its levels differ between the two types. Patients with systolic heart failure tend to have much higher BNP levels than those with diastolic heart failure. In one emergency-department study, average BNP was roughly 820 pg/ml in systolic heart failure but about 410 pg/ml in diastolic heart failure.⁵ That difference matters clinically because a “normal” BNP can lull doctors into missing diastolic heart failure.⁶ Yet when researchers compared patients who had the same BNP levels regardless of ejection fraction, the prognosis was equally poor in both groups.⁷ In other words, diastolic heart failure is not a milder disease just because the blood test number is lower.

Symptoms Overlap More Than You Would Expect

One of the most common misconceptions is that diastolic heart failure is somehow less symptomatic because the ejection fraction is preserved. From the patient’s perspective, that is not the case. Both types produce shortness of breath, fatigue, and exercise intolerance. When researchers put patients with each type through formal cardiopulmonary exercise testing, their peak oxygen consumption and breathing efficiency were almost identical, despite the marked difference in ejection fraction.⁸ Both groups were equally limited in what they could do physically. The symptoms that bring someone to the doctor, swollen ankles, trouble climbing stairs, waking up at night gasping for air, are the same regardless of which phase of the heartbeat is failing.

Who Tends to Get Which Type

The demographic profiles are strikingly different. Systolic heart failure skews younger and male. It more often follows a heart attack, and patients are more likely to have a history of smoking or a family history of premature coronary disease.⁹ Diastolic heart failure, by contrast, is more common in older adults, women, and people with hypertension, diabetes, and obesity.⁹

Data from the Framingham Heart Study put numbers on some of these patterns. Female sex roughly doubled the odds of having diastolic rather than systolic heart failure, and atrial fibrillation quadrupled them. A prior heart attack, on the other hand, dropped the odds of diastolic heart failure by about two-thirds, making systolic dysfunction far more likely in that setting.¹⁰

Why Women Are Disproportionately Affected by Diastolic Dysfunction

The sex skew in diastolic dysfunction deserves its own discussion because it goes deeper than the fact that women live longer. When the heart remodels under stress, women’s ventricles tend toward a thicker, stiffer, concentric pattern while men’s ventricles are more likely to dilate.¹¹ This sex-specific remodeling pathway pushes women toward diastolic dysfunction even with similar blood pressure loads. Estrogen may play a protective role earlier in life that, after menopause, gives way to accelerated stiffening. Adverse pregnancy outcomes and premature menopause are now recognized as sex-specific risk factors for heart failure with preserved ejection fraction.¹²

In a study of cardiac surgery patients, women were nearly five times more likely than men to have diastolic dysfunction after adjusting for age and other clinical factors, with the biggest gap appearing between ages 56 and 72.¹³ This is not a subtle difference. It means screening tools and clinical suspicion need to be calibrated differently depending on the patient’s sex.

Treatment Is Where the Differences Matter Most

For systolic heart failure, clinicians have a well-tested playbook. Guideline-directed medical therapy involves four main drug classes used together, and the benefit is robust: multiple large randomized trials have shown improved survival and fewer hospitalizations when patients are maintained on the full combination.¹⁴ A real-world analysis found that patients with reduced ejection fraction who were not on this therapy had roughly a 29 percent higher risk of death compared to those who were.¹⁵

Diastolic heart failure has historically been a therapeutic desert. The drugs that transform outcomes in systolic heart failure, such as ACE inhibitors, beta-blockers, and aldosterone antagonists, have not shown the same survival benefits when the ejection fraction is preserved. For years the only strategy was to manage blood pressure, reduce fluid with diuretics, and treat underlying conditions like diabetes and atrial fibrillation.

That changed with a class of drugs called SGLT2 inhibitors, originally developed for diabetes. In the landmark EMPEROR-Preserved trial, empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by about 21 percent compared with placebo in patients with preserved ejection fraction.¹⁶ A meta-analysis pooling data from multiple trials confirmed that SGLT2 inhibitors reduced heart failure hospitalizations by about 25 percent in this population, with high confidence in the finding.¹⁷ In a separate trial, dapagliflozin improved symptoms, physical limitations, and six-minute walk distance by a meaningful margin in patients with preserved ejection fraction.¹⁸ SGLT2 inhibitors are now the first drug class to show clear benefits across the entire heart failure spectrum, systolic and diastolic alike.

The Middle Category That Complicates the Binary

For years, heart failure was classified as either reduced or preserved ejection fraction. That clean split left out a sizable group of patients whose ejection fraction lands in the gray zone, roughly 41 to 49 percent. This category, now called heart failure with mildly reduced ejection fraction, accounts for about 12 to 13 percent of new heart failure cases.¹⁹

These patients share some characteristics with both groups. Their comorbidity profiles, including rates of hypertension, diabetes, and obesity, look more like the preserved-ejection-fraction group. But the high prevalence of coronary artery disease in these patients resembles the reduced-ejection-fraction group.²⁰ The cardiovascular event risk is lower than in full-blown systolic heart failure, but the risk of non-cardiac events like cancer or kidney disease is similar or even higher.²⁰

Ejection fraction also fluctuates over time. Among patients initially diagnosed in the mildly reduced category, about a quarter saw their ejection fraction decline below 40 percent on follow-up, while close to 45 percent improved to 50 percent or above.¹⁹ A single ejection fraction measurement is a snapshot, and patients can drift between categories. Emerging evidence suggests that those in the mildly reduced range may benefit from the same neurohormonal-blocking drugs used in full systolic heart failure.²¹

Arterial Stiffness and Its Role in Diastolic Dysfunction

The heart does not work in isolation. It pushes against whatever resistance the arteries present. As arteries stiffen with age, high blood pressure, and metabolic disease, the heart has to work harder during systole, which in turn impairs its ability to relax during diastole. Research has demonstrated a strong coupling between arterial stiffness and diastolic chamber stiffness, meaning the two stiffen together in a kind of feedback loop.²²

In a study examining carotid artery stiffness alongside echo measurements, arterial stiffness parameters correlated directly with markers of impaired filling. After accounting for multiple risk factors, arterial stiffness and age were the only independent predictors of early-stage diastolic dysfunction.²³ This vascular contribution helps explain why diastolic dysfunction is so closely linked to hypertension and aging, and why it can progress even when the heart muscle itself appears structurally normal on basic imaging.

Inflammation and Comorbidities Drive Diastolic Dysfunction Differently

Systolic heart failure often has a single dramatic cause: a massive heart attack kills off a swath of muscle, and the pump weakens. Diastolic dysfunction tends to develop more insidiously, driven by a web of overlapping conditions. The current model emphasizes that systemic low-grade inflammation, fueled by comorbidities like diabetes, high cholesterol, and kidney disease, damages the lining of the heart’s smallest blood vessels.²⁴

Animal research combining three common comorbidities found that even without obvious structural heart changes, the combination produced clear diastolic dysfunction through a cascade of inflammation, reduced blood vessel relaxation, increased oxidative stress, and collagen buildup in the heart wall.²⁵ Autoimmune inflammation also plays a role: in patients with rheumatoid arthritis and heart failure, higher disease activity scores correlated with worse diastolic filling patterns.²⁶ This inflammatory-microvascular pathway is a key reason why treating diastolic heart failure cannot rely on a single pill. The underlying conditions driving it need to be addressed simultaneously.

How Causes of Death Differ

The way each type of heart failure ultimately proves fatal also differs. In systolic heart failure, about two-thirds of deaths are cardiac in nature, with heart failure progression and sudden cardiac death accounting for the largest share. In diastolic heart failure, only about 38 percent of deaths are cardiac, while non-cardiac causes including cancer, respiratory disease, kidney failure, and infection account for the majority.²⁷ Cancer alone caused 17 percent of deaths in preserved-ejection-fraction patients compared with 9 percent in those with reduced ejection fraction.²⁷

This pattern makes clinical sense given the comorbidity burden. Patients with diastolic heart failure tend to be older and carry more metabolic and inflammatory conditions, each of which raises the risk of dying from something other than the heart itself. It also has practical implications: a narrow focus on cardiac medications without addressing the whole picture misses the bigger mortality threat for many of these patients.

Advanced Imaging Beyond the Echocardiogram

When echocardiography leaves questions unanswered, cardiac magnetic resonance imaging can fill gaps that matter for both types of dysfunction. CMR is considered the gold standard for detecting and quantifying fibrosis, the scarring that stiffens the heart wall.²⁸ A technique called late gadolinium enhancement reveals patches of replacement scar, the kind left after a heart attack, and helps distinguish ischemic from non-ischemic causes of systolic dysfunction.²⁹

For diastolic dysfunction, the relevant fibrosis is often diffuse rather than patchy: fine strands of collagen woven throughout the muscle rather than a single scar. Newer mapping techniques measure properties of the heart tissue itself and can detect this subtle, widespread stiffening that older imaging methods miss.³⁰ This distinction matters because replacement scar rarely reverses, while diffuse fibrosis driven by inflammation may be partially modifiable with aggressive treatment of the underlying conditions.

Why the Old Labels Are Fading

The terms “systolic dysfunction” and “diastolic dysfunction” remain useful shorthand, but the formal classification system has shifted toward ejection fraction categories: reduced (below 40 percent), mildly reduced (41 to 49 percent), and preserved (50 percent and above). Some experts have proposed even finer distinctions, with truly “normal” ejection fraction set at 55 percent or higher in men and 60 percent or higher in women, reflecting known sex-based differences in baseline heart function.²¹

Part of the reason for moving away from the systolic-versus-diastolic framing is that the two often coexist. A person with a dilated, weakly squeezing ventricle frequently also has impaired relaxation. And a stiff ventricle with preserved ejection fraction may harbor subtle systolic impairment detectable with advanced strain imaging even though the overall ejection fraction looks fine. The evolution of the definition of heart failure reflects decades of refining how clinicians match patients to treatments that work, rather than trying to fit everyone into one of two neat boxes.³¹